Performance and Safety of the Innofix® Screw (IF25) (IF25)

Performance and Safety of the Innofix® Screw as Part of Stabilization of a Non-displaced Pathologic Fracture (Complete or Impending) of the Pelvic Bone of Cancer Patients by Mini-invasive Percutaneous Fixation by Internal Cemented Screw

The purpose of this clinical investigation is to collect data about the safety and the performances of the InnoFix® screw : Clinical performances (Pain reduction due to the fracture treatment, maintenance of the stabilizaton of the treated fracture and mobility improvement) / Technical performances (Percutaneous implantation by mini-invasive approach, Efficiency of percutaneous implementation and efficiency of percuatneous cementing) / Safety performances (Preservation of the screw stability after implantation and preservation of the screw integrity after implantation). The safety and performance data about the InnoFix® screw will be used to obtain their CE marking according to the regulation (EU) 2017/745.

The principal objective of this clinical investigation is to assess the postoperative reduction in pain level of the patient at 6 weeks follow-up.

Study Overview

• Status: Not yet recruiting
• Conditions: Pathologic Fracture
• Intervention / Treatment: Device: Percutaneous fixation by internal cemented screw (InnoFix®)

• Study Type: Interventional
• Enrollment (Estimated): 34
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Frédéric DESCHAMPS; Phone Number: +33 (0)1 42 11 42 11; Email: frederic.deschamps@gustaveroussy.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The patient is 18 years old or more
• The patient is a cancer patient
• The patient needs a stabilization of a non-displaced pathologic fracture (complete or impending) of the pelvic bone
• The patient is symptomatic with musculoskeletal pain exacerbated during movement or weight bearing
• The patient has been informed and he has signed the informed consent
• The patient must be willing and able to comply with all study requirements including follow-up visits and radiographic assessments
• The patient is affiliated with the French social security system

Exclusion Criteria:

• The patient has got a displaced fracture or an unstable fracture justifying conventional surgical fixation
• The patient is a pregnant woman or considered getting pregnant during its investigation participation
• The patient presents medical conditions that could have an impact on the clinical investigation (under responsibility of the investigator)
• The patient has got one or more contraindications to general anaesthesia
• The patient has got an insufficient bone strength (severe osteoporosis, local infection, or tumor osteolysis) precluding a correct and long-term fixation
• The use of the InnoFix® screw can interfere with anatomical structures or physiological performances
• The patient has got an insufficient tissue coverage at the surgical site
• The patient has got a sepsis, fever, subcutaneous or cutaneous infection on the implantation way, deep abscess in contact with the fracture site
• The patient has got a mental or neuromuscular disorder that may cause fixation failure or postoperative complications
• The patient is allergic and/or hypersensitive to a component of the InnoFix® modules, of the InnoTool™ instruments and to the used cement
• The patient has got a haemostasis disorder ((INR >1.5, platelets <50x109/L)
• The patient participates to another clinical investigation
• The patient's life expectancy is lower than 6 months
• The patient is under guardianship, curatorship or legal protection
• The patient is deprived of liberty by a judicial or administrative decision

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Adult cancer patient with a non-displaced pelvic pathologic fracture; The fracture of the patients, treated with InnoFix® screw, is stabilized with a percutaneous fixation by internal cemented screw. This procedure is carried out by mini-invasive approach.	Device: Percutaneous fixation by internal cemented screw (InnoFix®); Percutaneous fixation by internal cemented screw

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of patients which have a pain reduction rate, at 6 weeks postoperatively, equal or superior to 30%	Pain reduction is measured with the VAS scale : Zero is equivalent to no pain and 10 indicates the worst possible pain	From the patient inclusion date to 6 weeks postoperatively

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of patients which have a pain reduction rate, at 6 months postoperatively, equal or superior to 30%	The pain is measured with the VAS scale: Zero is equivalent to no pain and 10 indicates the worst possible pain	From the patient inclusion date to 6 months postoperatively
Rate of postoperative stable fractures	Fracture stability is assessed with medical imaging: Length of fracture line in millieter (complete fracture) or fracture occurernce (impending fracture)	From end surgery to 6 weeks and 6 months postoperatively
Rate of patients which have a mobility improvement rate postoperatively	Mobility is measured with ECOG scale:	From the patient inclusion date to 6 weeks and 6 months postoperatively
Implantation success rate of the InnoFix® screw	Implantation succes is measured with medical imaging: Screw position compared to the fracture line and distance, in millimeters, of the distal tip of screw compared to the planned area and protrusion, in millimeters, of the proximal part of screw from the external cortex	At the end of surgery
Satisfaction rate of the radiologist regarding the efficiency of the percutaneous implementation	Efficiency of percutaneous implementation is based on the experiency of the radaiologist	At the end of surgery
Satisfaction rate of the radiologist regarding the efficiency of the percutaneous cementing	Efficiency of percutaneous cementing is based on the experiency of the radaiologist	At the end of surgery
Rate of stable InnoFix® screws postoperatively	Screw stability is measured with medical imaging: Screw displacement in millimeters and contact with anatomical structures or other implanted devices	From end surgery to 6 weeks and 6 months postoperatively
Rate of InnoFix® screws with their integrity preserved postoperatively	Screw integrity is measured with medical imaging: Disassembly, breakage or bending in millimeters	From end surgery to 6 weeks and 6 months postoperatively
Rate of patient which have had, at least, one adverse event in relation with the InnoFix® screw postoperatively	Adverse event reported	From the patient inclusion date to 6 months postoperatively
Rate of patient which have had, at least, one serious adverse event in relation with the InnoFix® screw postoperatively	Serious adverse event reported	From the patient inclusion date to 6 months postoperatively

Collaborators and Investigators

• Sponsor: Innoprod Medical
• Collaborators: EVAMED
• Investigators: Principal Investigator: Lambros TSELIKAS, Gustave ROUSSY Cancer Institute - Villejuif; Principal Investigator: Xavier BUY, BERGONIE Institute - Bordeaux; Principal Investigator: Roberto Luigi CAZZATO, Strasbourg Civil Hospital - Strasbourg

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2025
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: January 17, 2025
• First Submitted That Met QC Criteria: January 29, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 29, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Cancer; Pelvis; FICS
• Additional Relevant MeSH Terms: Wounds and Injuries; Fractures, Bone; Fractures, Spontaneous
• Other Study ID Numbers: IF25; 2025-A00016-43 (Registry Identifier: French clinical trials database [ANSM])

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Sponsor commitment to not transfert data outside the European Union

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No